<DOC>
	<DOCNO>NCT02660710</DOCNO>
	<brief_summary>The purpose study establish safety rituximab plus cyclophosphamide , doxorubicin , vincristine , prednisone ( R-CHOP ) HIV-infected HIV-uninfected diffuse large B-cell lymphoma ( DLBCL ) patient Malawi .</brief_summary>
	<brief_title>Rituximab Plus CHOP Chemotherapy Diffuse Large B-cell Lymphoma</brief_title>
	<detailed_description>The study single-center , non-randomized phase II clinical trial R-CHOP CD20-positive DLBCL , use Indian generic biosimilar rituximab , Reditux™ . The investigator enroll 40 adult patient age 18-60 year ( 20 HIV-infected CD4 count ≥ 100 cells/µL , 20 HIV-uninfected ) receive maximum 6-8 cycle R-CHOP 18-24 week . The primary goal study establish safety R-CHOP Malawi population . Secondary objective study include estimate complete response ( CR ) rate , progression-free survival ( PFS ) , overall survival ( OS ) . In addition , quality life , cost care , study patient characteristic , clinical outcome publish data region collect used evaluate cost-effectiveness R-CHOP . If investigator ' study support incorporate rituximab treatment regimens sub-Saharan Africa , strategy examine large trial , provide momentum increase access modern cancer medicine globally .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Informed consent obtain sign . Age 1860 year . ECOG performance status ( PS ) 02 . Histologically confirm CD20positive DLBCL , stage , bulky nonbulky disease . No prior treatment lymphoma . Willing documentation HIV status . CD4 count ≥ 100 cells/µL HIVinfected . Measurable disease physical exam . Adequate bone marrow renal hepatic function evidence follow : Absolute neutrophil count ( ANC ) ≥ 1,000/µL Platelet count ≥ 100,000/µL Creatinine ≤ 1.5 mg/dL Total bilirubin ≤ 2 mg/dL ( unless directly attributable lymphoma ) Able understand comply protocol requirement entire length study . Willing reside &lt; 50 kilometer Kamuzu Central Hospital ( KCH ) chemotherapy completion . Negative urine BHCG woman childbearing potential within 7 day prior start treatment . Fertile patient must use effective contraception ( condom barrier method , oral contraceptive , implantable contraceptive , intrauterine device ) six month completion treatment . Exclusion Criteria Pregnant nursing . Central nervous system ( CNS ) involvement lymphoma ( clinically cytologically confirm ) . Receiving anticancer investigational therapy study treatment , apart agent specify study protocol . Known cardiac disease include follow : New York Heart Association ( NYHA ) Grade II great congestive heart failure History myocardial infarction unstable angina within 6 month prior Day 1 History stroke transient ischemic attack within 6 month prior Day 1 Second active malignancy require systemic therapy . Hepatitis B virus ( HBV ) surfaceantigen positive . Other serious , ongoing , nonmalignant disease infection would opinion site investigator compromise protocol objective .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>single arm phase 2</keyword>
	<keyword>safety efficacy</keyword>
	<keyword>R-CHOP</keyword>
</DOC>